Centrum Medyczne Piasta 47
- Address
- lock Available on a paid plan
Centrum Medyczne Piasta 47 Sp. z o.o.
Centrum Medyczne Piasta 47 Sp. z o.o. is a specialized clinical research facility focused on advancing treatments for complex ophthalmological and endocrine-related conditions. The center demonstrates particular expertise in conducting pivotal clinical trials for vision-threatening disorders, with emphasis on innovative therapeutic approaches for conditions affecting both ocular health and systemic endocrine manifestations.
- Diabetic retinopathy treatment evaluation using novel pharmaceutical interventions
- Thyroid eye disease (TED) management, including chronic and treatment-resistant cases
- Safety and efficacy assessments of biologic therapies for rare ophthalmic conditions
The facility specializes in both acute and chronic phase studies, including extension trials for non-responder populations. Their research portfolio includes dose-response relationship studies and open-label extensions, with particular focus on Diabetic Retinopathy Severity Scale (DRSS) assessments and intravenous infusion protocols for complex ophthalmological disorders. This comprehensive approach positions the center as a key site for evaluating emerging therapies that address significant unmet medical needs in diabetic complications and thyroid-associated eye disease.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Viridian Therapeutics Inc.2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Centrum Medyczne Piasta 47
lock Showing 1 of 5 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (22153) Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | Bayer AG | Phase III | Not Recruiting | Sep 2023 | May 2025 |
IMP list
lock Showing 1 of 6 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Aflibercept | 2 | Unknown | 2023-09-13 | 2025-06-05 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.